2 reports

FILGRASTIM - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description FILGRASTIM NA NA FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) IS UNDER DEVELOPMENT FOR THE TREATMENT O

  • Biotech
  • Stem Cell
  • United States
  • World
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Hospital
  • In Vitro Diagnostic Reagent
  • Lung Cancer
  • Stem Cell
  • AB Science SA